Cardiovascular Disease in Women: Influence of Hormonal Replacement Therapy

  • Rogerio A. Lobo
Conference paper

Abstract

While the average age of menopause (approximately 51.3 years) has not changed for several centuries, life expectancy in the developed world has dramatically increased and now approaches 80 years. Fully one third of a woman’s life is currently spent in an estrogen-deficient state. As the world’s population increases, an increasing segment of the population is entering menopause or is already postmenopausal. In the United States, by the year 2015 it is estimated that 45% of the population will be over age 45 [1].

Keywords

Placebo Cholesterol Cortisol Progesterone Smoke 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    U.S. Senate Special Committee on Aging (1988) Aging america: trends and projections. United States Department of Health and Human Services, WashingtonGoogle Scholar
  2. 2.
    Sempos CT, Cleeman JI, Carroll MD et al. (1993) Prevalence of high blood cholesterol among U.S. adults: an update based on guidelines from the Second Report of the National Cholesterol Education Programm Adult Treatment Panel. JAMA 269: 3009PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB, Abbott RD (1987) Incidence and prognosis of myocardial infarction in women: the Framingham study. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA (eds). Coronary heart disease in women. National Heart, Lung, and Blood Institute, National Institutes of Health, BethesdaGoogle Scholar
  4. 4.
    American Heart Association (1993) 1993 heart and stroke facts statistics. American Heart Association, DallasGoogle Scholar
  5. 5.
    Kannel WB, Hjortland MC, McNamara PM et al. (1976) Menopause and the risk of cardiovascular disease: the Framingham study. Ann Intern Med 85: 447PubMedGoogle Scholar
  6. 6.
    Rosenberg L, Hennekens CH, Rosner B et al. (1981) Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 139: 47PubMedGoogle Scholar
  7. 7.
    Centerwall BS (1981) Premenopausal hysterectomy and cardiovascular disease. Am J Obstet Gynecol 139: 58PubMedGoogle Scholar
  8. 8.
    Kannel WB, Gordon T (1987) Cardiovascular effects of the menopause. In: Mishell DR Jr (ed). Menopause: physiology and pharmacology. Year Book Medical, Chicago, p 91Google Scholar
  9. 9.
    Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wmg RR (1989) Menopause and risk factors for coronary heart disease. N Engl J Med 321: 641PubMedCrossRefGoogle Scholar
  10. 10.
    Jensen J, Nilas L, Christiansen C (1990) Influence of menopause on serum lipids and lipoproteins. Maturitas 12: 321PubMedCrossRefGoogle Scholar
  11. 11.
    Lobo RA, Notelvitz M, Bernstein L, Khan FY, Ross RK, Paul WL (1992) Lp(a) lipoprotein: relationship to cardivascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol 166: 1182PubMedGoogle Scholar
  12. 12.
    Bush RL (1990) Noncontraceptive estrogen use and risk of cardiovascular dis¬ease: an overview and critique of the literature. In: Korenman SG (ed). The menopause. Biological and clinical consequences of.ovarian failure: evolution and management. Serono Symposium, Norwell, Massachusetts, p 211Google Scholar
  13. 13.
    Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH (1990) Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses’ Health Study. Am J Obstet Gynecol 163: 285PubMedGoogle Scholar
  14. 14.
    Paganini-Hill A; Ross RK, Henderson BE (1988) Postmenopausal oestrogen treatment and stroke: prospective study. Br Med J 297: 519CrossRefGoogle Scholar
  15. 15.
    Henderson BE, Ross RK, Paganini-Hill A, MackTM (1986) Estrogen use and cardiovascular disease. Am J Obstet Gynecol 154: 1181Google Scholar
  16. 16.
    Sullivan JM, Vander Zwaag R, Lemp GF et al. (1988) Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 108: 358PubMedGoogle Scholar
  17. 17.
    Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA (1988) Postemenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 115: 954PubMedCrossRefGoogle Scholar
  18. 18.
    Sullivan JM, Vander Zwaag R, Hughes JP et al. (1990) Estrogen replacement and coronary artery disease. Arch Intern Med 150: 2557PubMedCrossRefGoogle Scholar
  19. 19.
    Henderson BE, Paganini-Hill A, Ross RK (1991) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151: 75PubMedCrossRefGoogle Scholar
  20. 20.
    Wagner JD, Clarkson TB, Adams MR, Schwenke DC (1991) The effects of oral contraceptives on coronary artery LDL metabolism in female cynomolgus monkeys. Circulation 84 [Suppl II]: II–602Google Scholar
  21. 21.
    Adams MR, Clarkson TB, Koritnik DR et al. (1987) Contraceptives, steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 47: 1010PubMedGoogle Scholar
  22. 22.
    Williams JK, Adams MR, Klopfenstein HS (1990) Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 81: 1680PubMedCrossRefGoogle Scholar
  23. 23.
    Williams JR, Adams MR, Herrington DM, Clarkson TB (1991) The effects of short-term estrogen treatment on vascular responses of coronary arteries. Circulation 84 [Suppl II]: 11–272Google Scholar
  24. 24.
    Lang U, Baker RS, Fisher BK, Yang D, Clark KE (1993) Estrogen increases coronary blood flow and is antagonized by inhibitors of nitric oxide (abstr no P353). Presented at the 40th annual meeting of the Society For Gynecologic Investigation, March 31–April 3,1993, Toronto, OntarioGoogle Scholar
  25. 25.
    Steinleitner A, Stanczyk FZ, Levin JH et al. (1989) Decreased in vitro production of 6-keto-prostaglandin F1a by uterine arteries from postmenopausal women. Am J Obstet Gynecol 161: 1677PubMedGoogle Scholar
  26. 26.
    Makila UM, Wahlberg L, Vlinikka L, Ylikorkala O (1982) Regulation of prostacyclin and thromboxane production by human umbilical vessels. The effect of estradiol and progesterone in a superfusion model. Prostaglandins Leukot Med 8: 115PubMedCrossRefGoogle Scholar
  27. 27.
    Bourne T, Hillard TC, Whitehead MI, Crook D, Campbell S (1990) Estrogen, arterial status, and postmenopausal women. Lancet 335: 1470Google Scholar
  28. 28.
    Pines A, Fisman EZ, Levo Y et al. (1991) The effects of hormone replacement therapy in normal postmenopausal women: measurement of Doppler-derived parameters of aortic flow. Am J Obstet Gynecol 64: 806Google Scholar
  29. 29.
    Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S (1991) Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 338: 839PubMedCrossRefGoogle Scholar
  30. 30.
    Sarrel PM, Lindsay D, Rosano GMC, Poole-Wilson PA (1992) Angina and normal coronary arteries in women: gynecologic findings. Am J Obstet Gynecol 167: 467PubMedGoogle Scholar
  31. 31.
    Rosano GMC, Sarrel PM, Poole-Wilson P, Collins P (1993) Beneficial effect of estrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342: 133PubMedCrossRefGoogle Scholar
  32. 32.
    Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA (1993) Cardiovascular protection by estrogen — calcium antagonist effect? Lancet 341: 1264PubMedCrossRefGoogle Scholar
  33. 33.
    Ballejo G, SaleemTH, Khan-Dawood FS et al. (1983) The effect of sex steroids on insulin binding by target tissues in the rat. Contraception 28: 413PubMedCrossRefGoogle Scholar
  34. 34.
    Barrett-Connor E, Laakso M (1990) Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 10: 531PubMedCrossRefGoogle Scholar
  35. 35.
    Lmdheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA (1993) A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60: 664Google Scholar
  36. 36.
    Lindheim SR, Legro RS, Bernstein L et al. (1992) Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Obstet Gynecol 167: 1831PubMedGoogle Scholar
  37. 37.
    Mashchak CA, Lobo RA (1985) Estrogen replacement therapy and hypertension. J Repro Med 30 [Suppl 10]: 805Google Scholar
  38. 38.
    Luotola H (1983) Blood pressure and hemodynamics in postmenopausal women during estradiol-17ß substitution. Ann Clin Res 15: 1PubMedGoogle Scholar
  39. 39.
    Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C (1987) The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 76: 753PubMedCrossRefGoogle Scholar
  40. 40.
    Aylward M, Maddock J, Lewis PA, Rees PL (1977) Estrogen replacement the-rapy and blood clotting. Curr Med Res Opin 4 [Suppl 3]: 83CrossRefGoogle Scholar
  41. 41.
    Notelovitz M, Ware M (1982) Coagulation risks with postmenopausal estrogen therapy. In: Studd J (ed) Progress in obstetrics and gynecology, vol 2. Churchill Livingstone, EdinburghGoogle Scholar
  42. 42.
    Notelovitz M, Kitchens C, Ware MD et al. (1983) Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 62: 596PubMedGoogle Scholar
  43. 43.
    Devor M, Barrett-Connor E, Renvall M, Feigal D Jr, Ramsdell J (1992) Estro-gen replacement therapy and the risk of venous thrombosis. Am J Med 92: 275PubMedCrossRefGoogle Scholar
  44. 44.
    Lobo RA (1992) Estrogen and the risk of coagulopathy. Am J Med 92: 283PubMedCrossRefGoogle Scholar
  45. 45.
    Lobo RA (1991) Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73: 925PubMedCrossRefGoogle Scholar
  46. 46.
    Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325: 1196PubMedCrossRefGoogle Scholar
  47. 47.
    Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA (1988) A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 159: 1540PubMedGoogle Scholar
  48. 48.
    Subbiah MTR, Kessel B, Agrawal M, Raj an R, Abplanalp W, Rymaszewski Z (1993) Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 77: 1095PubMedCrossRefGoogle Scholar
  49. 49.
    Huovinen K, Autio S, Kaprio J (1988) Peroral lynestrenol and arterial disease in mentally retarded women. A case-control study based on autopsy findings. Acta Obstet Gynecol Scand 67: 211PubMedCrossRefGoogle Scholar
  50. 50.
    Falkeborn M, Persson I, Adami H-O et al. (1992) The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynecol 99: 821CrossRefGoogle Scholar
  51. 51.
    Lobo RA, Speroff L (1994) International Consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril (in press)Google Scholar
  52. 52.
    Moyer DL, de Lignieres B, Drigues P, Pez JP (1993) Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 59: 992Google Scholar
  53. 53.
    Lobo RA (1991) Which progestogen? What dosage? In: Proceedings of the Inter¬national Novo Nordisk Symposium on cardiovascular effects of hormone replacement therapy. Copenhagen, February 1–2,1991, Novo Nordisk A/S, p 97Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • Rogerio A. Lobo

There are no affiliations available

Personalised recommendations